ArticleFrontiers in cardiovascular medicine2026
Combined prognostic value of lipoprotein(a) and an integrated inflammatory-lipid index in patients with acute coronary syndrome and type 2 diabetes mellitus.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Lipoprotein(a) [Lp(a)] and inflammation are critical drivers of residual risk. We aimed to evaluate the combined prognostic value of Lp(a) and a novel Inflammatory-Lipid Index [defined as hs-CRP × (ApoB/ApoA1)] in patients with acute coronary syndrome (ACS) and type 2 diabetes mellitus (T2DM). Methods and results: A total of 1,910 patients with ACS and T2DM were analyzed over a median follow-up of 5.5 years. Multivariable Cox regression confirmed that both Lp(a) and the Inflammatory-Lipid Index were independent predictors of major adverse cardiovascular events (MACE). Restricted cubic splines revealed significant non-linear, positive correlations between these markers and MACE risk (both Conclusions: Concomitant elevation of Lp(a) and the Inflammatory-Lipid Index identifies a particularly high-risk phenotype among ACS patients with T2DM. This dual-biomarker approach significantly enhances cardiovascular risk stratification beyond traditional factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.